Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCZE3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $174,912
Award facts
- Contract value 100% obligated
- $174,911.80 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $174,911.80 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The delivery order, issued on January 7, 2026, with an ultimate completion date of January 29, 2026, carries no set-aside designation, indicating the award was made through unrestricted federal procurement competition. Performance will be executed in Park Ridge, Illinois, where the company maintains its headquarters and distribution operations.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support the Department of Defense's pharmaceutical supply requirements globally. The parent IDC, valued at $499.999 billion with a completion date of December 31, 2036, authorizes DLA to issue delivery orders for a comprehensive range of pharmaceutical products to military healthcare facilities worldwide. DMS Pharmaceutical Group's selection as a prime vendor contractor and its demonstrated performance across multiple therapeutic categories, including oncology treatments such as Keytruda, positions the company as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FCZE3?
SPE2DR26FCZE3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 7, 2026.
How much is contract SPE2DR26FCZE3 worth?
The government has obligated $174,912 on SPE2DR26FCZE3.
Is contract SPE2DR26FCZE3 an order under another contract?
Yes. SPE2DR26FCZE3 is a delivery order under SPE2DR25D9127, an indefinite delivery contract.
Was contract SPE2DR26FCZE3 competed?
The extent of competition for SPE2DR26FCZE3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award